The company also posted an 8% higher profit, at RON16.4 million, and a 3.5% higher turnover, at RON89.4 million.
At the same time, Antibiotice’s external markets rose 18% to RON54.5 million.
According to market research company Cegedim, in January-June 2016, Antibiotice climbed one spot and ranks 12th among the 300 pharmaceutical companies operating in Romania.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53% stake, regional investment fund SIF Oltenia holds a 13.5% stake, and the remaining shares are distributed among other shareholders on the local capital market, among which investment funds Broadhurst Investments Limited, SIF Transilvania and SIF Banat-Crisana, as well as pension funds Alico, AZT Viitorul Tau/Allianz and Aripi/Generali.